These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36644508)

  • 1. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI study.
    Ray KK; Haq I; Bilitou A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Hildebrandt P; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
    Atheroscler Plus; 2021 Sep; 43():24-30. PubMed ID: 36644508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.
    Ray KK; Haq I; Bilitou A; Manu MC; Burden A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL;
    Lancet Reg Health Eur; 2023 Jun; 29():100624. PubMed ID: 37090089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment and LDL cholesterol adjustment in patients with high and very high cardiovascular risk in Germany compared with Europe - data from the SANTORINI registry].
    Stürzebecher PE; Tünnemann-Tarr A; Tuppatsch K; Laufs U
    Dtsch Med Wochenschr; 2023 Apr; 148(9):55-64. PubMed ID: 36858065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
    Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
    Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
    Vallejo-Vaz AJ; Bray S; Villa G; Brandts J; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Kees Hovingh G; Jozwiak JJ; Jukema JW; Gabor Kiss R; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR; Ray KK;
    Cardiovasc Drugs Ther; 2023 Oct; 37(5):941-953. PubMed ID: 35567726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
    Ray KK; Molemans B; Schoonen WM; Giovas P; Bray S; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Hovingh GK; Jozwiak JJ; Jukema JW; Kiss RG; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR;
    Eur J Prev Cardiol; 2021 Sep; 28(11):1279-1289. PubMed ID: 33580789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
    van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
    Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study.
    Gouni-Berthold I; Schaper F; Schatz U; Tabbert-Zitzler A; Fraass U; Sauer S; Ray KK
    Atheroscler Plus; 2022 Dec; 50():10-16. PubMed ID: 36643801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FACTORS INFLUENCING ACHIEVEMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS IN MEXICO: THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY.
    Bello-Chavolla OY; Aguilar-Salinas CA
    Rev Invest Clin; 2019; 71(6):408-416. PubMed ID: 31823964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid management across Europe in the real-world setting: a rapid evidence review.
    Barrios V; Soronen J; Carter AM; Anastassopoulou A
    Curr Med Res Opin; 2021 Dec; 37(12):2049-2059. PubMed ID: 34517739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data.
    Gavina C; Carvalho DS; Pardal M; Afonso-Silva M; Grangeia D; Dinis-Oliveira RJ; Araújo F; Taveira-Gomes T
    J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.
    Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Gao Q; Palagashvilli T; Alam S; Mues KE; Bhatt DL; Kosiborod MN;
    JAMA Cardiol; 2021 Sep; 6(9):1060-1068. PubMed ID: 34132735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Room for improvement: initiation of lipid-lowering treatment and achievement of lipid target levels-a Danish registry-based study.
    Rerup SA; Rørth R; Bang LE; Mogensen UM; Torp-Pedersen C; Gislason G; Køber L; Fosbøl EL
    Eur Heart J Qual Care Clin Outcomes; 2021 Mar; 7(2):181-188. PubMed ID: 31958115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
    Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
    Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
    Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
    BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.